Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Joseph P. Nkolola et al.|The Lancet|2018Cited by 342
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R. Baden, Hong‐Van Tieu, Daniel J Stieh et al.|The Lancet HIV|2020Cited by 91
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R. Baden, Kelly Stanley, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2018Cited by 45
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a StudyDaniel J Stieh, Varun K. Phadke, Dan H. Barouch et al.|The Journal of Infectious Diseases|2022Cited by 36